GSK completes production-line upgrade; U.K. to boost Big Pharma appeal;

> GlaxoSmithKline ($GSK) has completed a three-year, $7-million upgrade of two production lines at a plant in Brasov, Romania. Item

> BioMarin Pharmaceutical will double the capacity of its Novato, CA, plant to produce $1 billion in products, including biggest seller Naglazyme. Item

> Six drug-delivery technologies are helping drugmakers extend patents: affinity-based targeting, controlled/sustained-release systems, passive delivery, active device delivery, passive device delivery and processing technologies. Release

> Tanzania is set to begin production of generic antiretroviral drugs in a new multi-million-dollar manufacturing plant in Arusha. Story

> Vivimed Labs of Hyderabad, India, has acquired Uquifa, a manufacturer of APIs and intermediates with operations in Spain and Mexico. Article

> Norbert Dentressangle has opened a shared-user cold store facility in the south of France. Story

> A groundbreaking ceremony on Friday signaled the construction start of a $394 million Chengdu, Sichuan, China cold-chain logistics center, which will boast 160,000 square meters of distribution space. Article

> The U.K.'s FDS Pharma has acquired the Rehovot hepatitis vaccine manufacturing plant of SciGen Israel for $2 million plus 5% royalties on sales. Story

> Millstone Medical Outsourcing said it will provide freezer storage and cold chain distribution services for customers' biologic products from a Memphis, TN-based facility. Story

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.